INCB053914

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaSolid Tumors

Phase 1

Study of INCB053914 in Subjects With Advanced Malignancies

TerminatedNCT02587598

Incyte CorporationSolid Tumors

Start: 2015-12-29End: 2020-08-11Updated: 2021-12-08

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

CompletedNCT03688152

Incyte CorporationRefractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma

Start: 2018-12-03End: 2020-09-01Updated: 2020-11-10

Related Papers

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.

2023-05-154 citations

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Blood2017-12-078 citations